Ozempic vs Mounjaro lawsuit — this is one of the most common questions in GLP-1 drug litigation today. Both drugs face thousands of lawsuits in federal court. Both target the same biological pathway. However, the cases involve different manufacturers, different active ingredients, and potentially different legal outcomes. If you suffered serious side effects from either drug, understanding the Ozempic vs Mounjaro lawsuit differences matters. This comparison breaks down what separates these two tracks of multidistrict litigation in 2026.
What Is the Ozempic Lawsuit?
The Ozempic lawsuit targets Novo Nordisk, the maker of Ozempic, Wegovy, and Rybelsus. These drugs all contain semaglutide, a GLP-1 receptor agonist. Plaintiffs allege Novo Nordisk failed to warn patients about severe gastrointestinal injuries. The most common claims involve gastroparesis, ileus, and bowel obstruction. The FDA updated the Ozempic label in 2023 to include ileus as a side effect. However, plaintiffs argue this warning came too late.
As of May 2026, over 3,636 lawsuits are pending in MDL 3094 in the Eastern District of Pennsylvania. Judge Karen Spencer Marston presides over the litigation. A separate MDL 3163 handles vision loss claims related to NAION. That smaller MDL includes 86 cases. The court has scheduled a Science Day for June 2, 2026. No bellwether trials have started yet.
The FDA also sent a warning letter to Novo Nordisk. The agency flagged potential failures in reporting side effects. This adds weight to the failure-to-warn claims at the heart of the litigation. Plaintiffs must show they suffered a qualifying injury confirmed by diagnostic testing. A gastric emptying study is now required for gastroparesis claims.
What Is the Mounjaro Lawsuit?
The Mounjaro lawsuit targets Eli Lilly and Company. Mounjaro and its weight-loss version, Zepbound, both contain tirzepatide. Unlike semaglutide, tirzepatide is a dual-action drug. It targets both GLP-1 and GIP receptors. This different mechanism is a key factor in how these cases may play out. On the other hand, plaintiffs report many of the same injuries as Ozempic users.
Mounjaro cases are consolidated in the same MDL 3094 alongside Ozempic claims. This means both drugs share the same judge and the same procedural timeline. Similarly, Mounjaro vision loss claims fall under MDL 3163. The core legal theory is identical — failure to warn. Plaintiffs say Eli Lilly knew or should have known about the risks. They allege the company did not place adequate warnings on the label.
Mounjaro lawsuits allege serious injuries including gastroparesis, severe pancreatitis, kidney injury, and intestinal obstruction. While the drug mechanism differs from Ozempic, the injuries overlap significantly. No global settlement has been reached. Bellwether trial selection is expected later in 2026. Consulting a licensed mass tort attorney is essential if you believe you have a claim.
Ozempic vs Mounjaro Lawsuit — Key Differences
| Factor | Ozempic (Novo Nordisk) | Mounjaro (Eli Lilly) |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug mechanism | GLP-1 receptor agonist only | Dual GLP-1 and GIP receptor agonist |
| Federal MDL (GI injuries) | MDL 3094 — E.D. Pennsylvania | MDL 3094 — same MDL |
| Federal MDL (vision loss) | MDL 3163 — E.D. Pennsylvania | MDL 3163 — same MDL |
| Pending GI cases (May 2026) | Majority of 3,636 total cases | Included in the 3,636 total |
| FDA label history | Ileus added Sept. 2023; FDA warning letter issued | Similar GI warnings on label |
| Bellwether trial timeline | Selection expected late 2026 | Selection expected late 2026 |
| Settlement status | No global settlement yet | No global settlement yet |
The most important Ozempic vs Mounjaro lawsuit difference is the drug mechanism. Ozempic targets only the GLP-1 receptor. Mounjaro targets both GLP-1 and GIP receptors. This dual-action design could affect how juries evaluate causation. In contrast, the procedural path is nearly identical. Both sets of cases sit in the same MDL before the same judge. The settlement process will likely follow the same timeline for both drugs.
While both lawsuits share the failure-to-warn theory, the defendants are different companies. Novo Nordisk received an FDA warning letter about underreporting side effects. This fact may strengthen Ozempic-specific claims. However, Eli Lilly faces its own scrutiny over tirzepatide safety data. Each company’s internal communications will be examined separately. Understanding which Ozempic vs Mounjaro lawsuit track applies to you depends on which drug you took.
How GLP-1 Drug Cases Move Through MDL Court
Both the Ozempic vs Mounjaro lawsuit cases proceed as mass torts, not class actions. In a mass tort versus a class action, each plaintiff files an individual claim. Your case is evaluated based on your specific injuries. The MDL structure groups cases together for pretrial efficiency. Discovery, expert disputes, and motions are handled once — not thousands of times. This is the same approach used in major cases like the Roundup lawsuit and the AFFF firefighting foam litigation.
Bellwether trials are the next major milestone. The court will select a small number of representative cases. These trials test the strength of key arguments. Their outcomes often drive settlement negotiations. For the Ozempic vs Mounjaro lawsuit, bellwether selection is expected in late 2026. Actual trials may not begin until 2027. The statute of limitations varies by state. Filing sooner is always better than waiting.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Which One Applies to Your Situation
The answer to the Ozempic vs Mounjaro lawsuit question is straightforward. It depends on which drug you used. If you took Ozempic, Wegovy, or Rybelsus and developed serious side effects, your claim falls under the Novo Nordisk track. If you took Mounjaro or Zepbound and suffered similar injuries, your claim targets Eli Lilly. Both tracks are part of the same MDL. Both follow the same procedural timeline.
You may qualify for an Ozempic vs Mounjaro lawsuit if you experienced gastroparesis, bowel obstruction, ileus, pancreatitis, gallbladder removal, or vision loss after taking either drug. Diagnostic confirmation is required. A gastric emptying study is necessary for gastroparesis claims. Similarly, NAION must be documented by an eye specialist. The eligibility requirements focus on provable, documented injuries — not mild side effects.
If you are unsure which path fits your situation, take the eligibility quiz to get started. A licensed attorney can review your medical records and determine the best approach. Whether your case falls on the Ozempic or Mounjaro side, the core question is the same. Did the manufacturer fail to warn you? An experienced mass tort lawyer can help you answer that question and pursue potential recovery.
Frequently Asked Questions
Are Ozempic and Mounjaro lawsuits in the same MDL?
Yes. Both the Ozempic vs Mounjaro lawsuit tracks are consolidated in MDL 3094 in the Eastern District of Pennsylvania. GI injury claims for both drugs share the same judge and schedule. Vision loss claims are in a separate MDL 3163. While the drugs have different manufacturers, the court handles them together for pretrial efficiency. Other large MDLs like the hernia mesh litigation and Camp Lejeune water contamination case follow similar consolidation structures.
Can I file a lawsuit if I took both Ozempic and Mounjaro?
Potentially, yes. Some patients switched from one drug to the other. If you developed qualifying injuries, you may have claims against both Novo Nordisk and Eli Lilly. An Ozempic vs Mounjaro lawsuit involving both drugs adds complexity. A licensed attorney can evaluate which manufacturer bears responsibility based on when your injuries appeared. Each case depends on your specific medical timeline and records.
When will settlements happen in the GLP-1 litigation?
No global settlement has been announced in the Ozempic vs Mounjaro lawsuit as of May 2026. Bellwether trial selection is expected later this year. Actual trials may begin in 2027. Settlement talks usually accelerate after bellwether verdicts. The timeline could stretch into 2028 or beyond. However, you should not wait to file. The statute of limitations can expire while you delay. Consulting an attorney now protects your rights and any potential recovery.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
- All Active MDL Cases
- More in This Category
- Tort Reform by State — 50-State Comparison
- All 50 State Tort Reform Guides
- Mass Tort Explainers
- Demographic Guides
- Mass Tort Tips
- Florida Tort Reform Guide
- Texas Tort Reform Guide
- North Carolina Tort Reform Guide
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.